TNXP vs. VAXX, TRAW, COCP, TLPH, AYTU, VBIV, NERV, VINC, INDP, and NRSN
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Vaxxinity (VAXX), Traws Pharma (TRAW), Cocrystal Pharma (COCP), Talphera (TLPH), Aytu BioPharma (AYTU), VBI Vaccines (VBIV), Minerva Neurosciences (NERV), Vincerx Pharma (VINC), Indaptus Therapeutics (INDP), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical preparations" industry.
Vaxxinity (NASDAQ:VAXX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Vaxxinity has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
83.0% of Vaxxinity shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 59.1% of Vaxxinity shares are owned by company insiders. Comparatively, 0.5% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Vaxxinity. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 2 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.90 beat Tonix Pharmaceuticals' score of 0.84 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.
Tonix Pharmaceuticals received 334 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 63.96% of users gave Tonix Pharmaceuticals an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Vaxxinity has higher earnings, but lower revenue than Tonix Pharmaceuticals. Vaxxinity is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vaxxinity presently has a consensus price target of $7.00, suggesting a potential upside of 5,862.52%. Tonix Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 2,800.84%. Given Tonix Pharmaceuticals' higher possible upside, research analysts plainly believe Vaxxinity is more favorable than Tonix Pharmaceuticals.
Vaxxinity's return on equity of -87.67% beat Tonix Pharmaceuticals' return on equity.
Summary
Tonix Pharmaceuticals beats Vaxxinity on 9 of the 16 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
